Senate clears way for von Eschenbach vote

Share this article:
The US Senate today voted to end debate on the nomination of Andrew von Eschenbach to permanently head the FDA, clearing the way for a final vote. Von Eschenbach supporters overcame objections from three Republican senators who opposed his nomination. In a procedural move, the Senate voted, 89-6, to end debate over the nomination. A Senate vote to confirm von Eschenbach as FDA commissioner was expected later today, Reuters reported. Von Eschenbach has served as acting FDA commissioner since September 2005. He was nominated earlier this year by President Bush to take the job permanently.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.